NCT04985110 is a Phase 2 clinical trial of Cotrimoxazole in Prostate Cancer, sponsored by Indonesia University.

Who is sponsoring NCT04985110?

NCT04985110 is sponsored by Indonesia University.

What drugs are being tested in NCT04985110?

Interventions in NCT04985110: Cotrimoxazole, Placebo.

What condition does NCT04985110 study?

NCT04985110 studies Prostate Cancer, Prostate Biopsy, Perioperative Complication, Bacteriuria, Urinary Tract Infections, Sepsis.

Is NCT04985110 still recruiting?

NCT04985110 is currently status unknown. Last updated 5 August 2021.

Last reviewed 2021-08-05 · How we verify

NCT04985110

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital

Status unknown Phase 2 Last updated 5 August 2021

What this trial tests

Phase 2 trial testing Cotrimoxazole in Prostate Cancer in 78 participants. Status unknown.

Timeline

6 July 2021

Primary endpoint
6 July 2023

6 July 2023

Quick facts

Lead sponsor	Indonesia University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	78
Start date	6 July 2021
Primary completion	6 July 2023
Estimated completion	6 July 2023
Sites	1 location across Indonesia

Drugs / interventions tested

Cotrimoxazole — full drug profile →
Placebo

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Prostate Biopsy — all drugs for Prostate Biopsy →
Perioperative Complication — all drugs for Perioperative Complication →
Bacteriuria — all drugs for Bacteriuria →

Sponsor

Indonesia University

Who can join

45 and older, male only, with Prostate Cancer or Prostate Biopsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial aims to compare the rate of perioperative infection complications in transperineal prostate biopsy between the group that receives prophylactic antibiotic and the group that receives placebo. The types of infection studied included bacteriuria, urinary tract infection (UTI), UTI with fever (febrile UTI), and sepsis. This study hypothesized that the administration of prophylactic antibiotics during transperineal prostate biopsy would result in lower rates of perioperative infection complications.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Infectious complications following transperineal prostate biopsy with or without periprocedural antibiotic prophylaxis-a systematic review including meta-analysis of all comparative studies.
Wolff I, Büchner M, Hauner K, Wagenlehner F, et al · · 2026 · cited 5× · PMID 39741175 · DOI 10.1038/s41391-024-00934-9

Verify or expand the search:

Other trials of Cotrimoxazole

Trials testing the same drug.

NCT03187834 — Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso · Phase 4 · completed
NCT03087890 — Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria · Phase 4 · completed
NCT01777737 — Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole · Phase 3 · terminated

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Indonesia University trials

Trials by the same sponsor.

NCT07137130 — Secretome TGF Beta 3 · NA · not yet recruiting
NCT07420335 — Preoperative Shoulder Exercises and Postoperative Inflammation, Pain, and Function After Modified Radical Mastectomy · NA · not yet recruiting
NCT07278284 — The Effectiveness of Press Needle Acupuncture on Preoperative Anxiety in Tympanoplasty and Mastoidectomy · NA · recruiting
NCT07337187 — Effect of Thread-Embedding Acupuncture at EX-B2 on Pain and Quality of Life in Chronic Low Back Pain · NA · not yet recruiting
NCT07242001 — Laser Acupuncture for Otitis Media With Effusion in Children · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04985110 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Indonesia University
Last refreshed: 5 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04985110.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing